{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:52Z","timestamp":1783075972109,"version":"3.54.6"},"reference-count":147,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1097\/ftd.0b013e31819f3328","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T15:07:41Z","timestamp":1242918461000},"page":"283-318","source":"Crossref","is-referenced-by-count":46,"title":["Pharmacokinetics and Therapeutic Drug Monitoring of Psychotropic Drugs in Pediatrics"],"prefix":"10.1097","volume":"31","author":[{"given":"Simona","family":"Pichini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Papaseit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Joya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Vall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mag\u00ed","family":"Farr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Garcia-Algar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"de laTorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl 1","key":"R2-2-20210129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-198900171-00004","article-title":"Clinical pharmacology of the perinatal period and early infancy.","volume":"17","author":"Morselli","year":"1989","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"R3-2-20210129","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2165\/00003088-198900171-00005","article-title":"Clinical pharmacokinetics in infants and children. A reappraisal.","volume":"17","author":"Kearns","year":"1989","journal-title":"Clin Pharmacokinet"},{"key":"R4-2-20210129","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1542\/pir.13-11-413","article-title":"Pediatric pharmacokinetics and therapeutic drug monitoring.","volume":"13","author":"McLeod","year":"1992","journal-title":"Pediatr Rev"},{"key":"R5-2-20210129","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/toxsci\/66.2.185","article-title":"Evaluation of child\/adult pharmacokinetic differences from a database derived from the therapeutic drug literature.","volume":"66","author":"Ginsberg","year":"2002","journal-title":"Toxicol Sci"},{"key":"R6-2-20210129","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.drudis.2006.03.002","article-title":"New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology.","volume":"11","author":"Stevens","year":"2006","journal-title":"Drug Discov Today"},{"key":"R7-2-20210129","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology-drug disposition, action, and therapy in infants and children.","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"},{"key":"R8-2-20210129","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2165\/00003088-199529050-00004","article-title":"Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.","volume":"29","author":"Battino","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"R9-2-20210129","first-page":"1","article-title":"Neurology of the newborn.","volume":"22","author":"Volpe","year":"1981","journal-title":"Major Probl Clin Pediatr"},{"key":"R10-2-20210129","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF00607431","article-title":"Pharmacokinetics of phenobarbital in childhood.","volume":"12","author":"Heimann","year":"1977","journal-title":"Eur J Clin Pharmacol"},{"key":"R11-2-20210129","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/cpt1978233346","article-title":"Phenobarbital pharmacokinetics in neonates.","volume":"23","author":"Pitlick","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"R12-2-20210129","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1212\/WNL.31.8.1042","article-title":"Phenobarbital maintenance dose requirements in treating neonatal seizures.","volume":"31","author":"Fischer","year":"1981","journal-title":"Neurology"},{"key":"R13-2-20210129","first-page":"279","article-title":"Pharmacokinetics and relative bioavailability of intramuscular phenobarbital sodium or acid in infants.","volume":"1","author":"Minagawa","year":"1981","journal-title":"Pediatr Pharmacol (New York)"},{"key":"R14-2-20210129","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000457062","article-title":"Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data.","volume":"8","author":"Grasela","year":"1985","journal-title":"Dev Pharmacol Ther"},{"key":"R15-2-20210129","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0928-0987(00)00145-7","article-title":"Clinical pharmacokinetics of phenobarbital in neonates.","volume":"12","author":"Touw","year":"2000","journal-title":"Eur J Pharm Sci"},{"key":"R16-2-20210129","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-2125.2003.01951.x","article-title":"Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions.","volume":"56","author":"Kokwaro","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"R18-2-20210129","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/00003088-198308050-00005","article-title":"First-dose and steady-state pharmacokinetics of valproic acid in children with seizures.","volume":"8","author":"Hall","year":"1983","journal-title":"Clin Pharmacokinet"},{"key":"R19-2-20210129","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0022-3476(85)80097-4","article-title":"Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug treatment.","volume":"106","author":"Chiba","year":"1985","journal-title":"J Pediatr"},{"key":"R20-2-20210129","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1212\/WNL.38.3.467","article-title":"Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures.","volume":"38","author":"Gal","year":"1988","journal-title":"Neurology"},{"key":"R21-2-20210129","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0887-8994(03)00019-5","article-title":"Rapid infusion of sodium valproate in acutely ill children.","volume":"28","author":"Birnbaum","year":"2003","journal-title":"Pediatr Neurol"},{"key":"R22-2-20210129","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.pediatrneurol.2003.12.006","article-title":"Divalproex-ER pharmacokinetics in older children and adolescents.","volume":"30","author":"Dutta","year":"2004","journal-title":"Pediatr Neurol"},{"key":"R23-2-20210129","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.mjt.0000155113.89092.58","article-title":"Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children.","volume":"13","author":"Panomvana Na Ayudhya","year":"2006","journal-title":"Am J Ther"},{"key":"R24-2-20210129","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/BF00542419","article-title":"Clonazepam pharmacokinetics and therapeutic efficacy in neonatal seizures.","volume":"30","author":"Andre","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"R25-2-20210129","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/00007691-200208000-00012","article-title":"Pharmacokinetic and pharmacodynamic effects of clonazepam in children with epilepsy treated with valproate: a preliminary study.","volume":"24","author":"Wang","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R26-2-20210129","first-page":"8","article-title":"Quantitative study of EEG (power spectrum changes induced by diazepam in epileptic patients).","volume":"2","author":"Huang","year":"1993","journal-title":"J Clin Electroencephalogr"},{"key":"R27-2-20210129","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2165\/00003495-199141060-00007","article-title":"Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.","volume":"41","author":"Grant","year":"1991","journal-title":"Drugs"},{"key":"R28-2-20210129","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2125.1990.tb03772.x","article-title":"Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl GABA) in epileptic children.","volume":"30","author":"Rey","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"R29-2-20210129","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/00003088-199223040-00003","article-title":"Vigabatrin. Clinical pharmacokinetics.","volume":"23","author":"Rey","year":"1992","journal-title":"Clin Pharmacokinet"},{"key":"R30-2-20210129","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2125.1996.00495.x","article-title":"Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures.","volume":"42","author":"Vauzelle-Kervroedan","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"R31-2-20210129","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00007691-199710000-00001","article-title":"Vigabatrin serum concentration to dosage ratio: influence of age and associated antiepileptic drugs.","volume":"19","author":"Armijo","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R32-2-20210129","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1528-1157.1993.tb02387.x","article-title":"Phenytoin monitoring in status epilepticus in infants and children.","volume":"34","author":"Richard","year":"1993","journal-title":"Epilepsia"},{"key":"R33-2-20210129","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/archneur.1974.00490400090012","article-title":"Intramuscular administration of diphenylhydantoin. Histologic follow-up studies.","volume":"31","author":"Serrano","year":"1974","journal-title":"Arch Neurol"},{"key":"R34-2-20210129","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/j.1875-9114.1994.tb02788.x","article-title":"Venous irritation related to intravenous administration of phenytoin versus fosphenytoin.","volume":"14","author":"Jamerson","year":"1994","journal-title":"Pharmacotherapy"},{"key":"R35-2-20210129","first-page":"635","article-title":"Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration.","volume":"54","author":"Ogutu","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"R36-2-20210129","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1046\/j.1365-2125.2003.01829.x","article-title":"Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus.","volume":"56","author":"Ogutu","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"R37-2-20210129","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1469-8749.1988.tb04809.x","article-title":"Benign partial epilepsy-treatment with sulthiame.","volume":"30","author":"Doose","year":"1988","journal-title":"Dev Med Child Neurol"},{"key":"R38-2-20210129","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00007691-199406000-00005","article-title":"Pharmacokinetics of sulthiame in epileptic patients.","volume":"16","author":"May","year":"1994","journal-title":"Ther Drug Monit"},{"key":"R39-2-20210129","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0920-1211(92)90065-2","article-title":"An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels.","volume":"13","author":"Cheung","year":"1992","journal-title":"Epilepsy Res"},{"key":"R40-2-20210129","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1365-2125.1996.31610.x","article-title":"Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children.","volume":"41","author":"Vauzelle-Kervroedan","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"R41-2-20210129","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1528-1157.1996.tb00650.x","article-title":"Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy.","volume":"37","author":"Eriksson","year":"1996","journal-title":"Epilepsia"},{"key":"R42-2-20210129","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1592\/phco.19.6.437.31052","article-title":"Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs.","volume":"19","author":"Chen","year":"1999","journal-title":"Pharmacotherapy"},{"key":"R43-2-20210129","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00007691-200106000-00006","article-title":"Single-dose pharmacokinetics of lamotrigine in children: influence of age and antiepileptic comedication.","volume":"23","author":"Battino","year":"2001","journal-title":"Ther Drug Monit"},{"key":"R44-2-20210129","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jocn.2005.12.037","article-title":"Monitoring salivary lamotrigine concentrations.","volume":"13","author":"Malone","year":"2006","journal-title":"J Clin Neurosci"},{"key":"R45-2-20210129","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1212\/WNL.48.4.1032","article-title":"A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures.","volume":"48","author":"Gustavson","year":"1997","journal-title":"Neurology"},{"issue":"Suppl 1","key":"R46-2-20210129","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1177\/0883073897012001031","article-title":"Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in?","volume":"12","author":"Coulter","year":"1997","journal-title":"J Child Neurol"},{"issue":"Suppl 4","key":"R47-2-20210129","first-page":"38","article-title":"Topiramate selectively blocks kainate currents in cultured hippocampal neurons.","volume":"36","author":"Severt","year":"1995","journal-title":"Epilepsia"},{"issue":"Suppl 2","key":"R48-2-20210129","first-page":"122","article-title":"The novel anticonvulsant topiramate enhances GABA mediated chloride flux.","volume":"34","author":"Brown","year":"1993","journal-title":"Epilepsia"},{"key":"R49-2-20210129","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1528-1157.1999.tb00780.x","article-title":"Topiramate pharmacokinetics in infants.","volume":"40","author":"Glauser","year":"1999","journal-title":"Epilepsia"},{"key":"R50-2-20210129","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0887-8994(99)00011-9","article-title":"A study of topiramate pharmacokinetics and tolerability in children with epilepsy.","volume":"20","author":"Rosenfeld","year":"1999","journal-title":"Pediatr Neurol"},{"key":"R51-2-20210129","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/08830738010160110501","article-title":"Clinical experience with topiramate dosing and serum levels in children 12 years or under with epilepsy.","volume":"16","author":"Schwabe","year":"2001","journal-title":"J Child Neurol"},{"key":"R52-2-20210129","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0887-8994(03)00048-1","article-title":"Topiramate concentration in saliva: an alternative to serum monitoring.","volume":"29","author":"Miles","year":"2003","journal-title":"Pediatr Neurol"},{"key":"R53-2-20210129","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/00007691-200312000-00008","article-title":"Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response.","volume":"25","author":"Ferrari","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R54-2-20210129","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/j.0013-9580.2004.65503.x","article-title":"Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years.","volume":"45","author":"Mikaeloff","year":"2004","journal-title":"Epilepsia"},{"key":"R55-2-20210129","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00007691-200406000-00005","article-title":"Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications.","volume":"26","author":"Adin","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R56-2-20210129","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00003088-200544040-00005","article-title":"Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data.","volume":"44","author":"Battino","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R57-2-20210129","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.seizure.2005.11.003","article-title":"Clinical experience with topiramate dosing and serum levels in patients with epilepsy.","volume":"15","author":"Zanotta","year":"2006","journal-title":"Seizure"},{"key":"R58-2-20210129","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/0920-1211(91)90068-Q","article-title":"Comparison of gabapentin with other antiepileptic and GABAergic drugs.","volume":"8","author":"Kondo","year":"1991","journal-title":"Epilepsy Res"},{"key":"R59-2-20210129","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/00912700122010384","article-title":"Single-dose gabapentin pharmacokinetics and safety in healthy infants and children.","volume":"41","author":"Haig","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"R60-2-20210129","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2710.2004.00596.x","article-title":"Pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures.","volume":"29","author":"Tallian","year":"2004","journal-title":"J Clin Pharm Ther"},{"key":"R61-2-20210129","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0163-7258(95)00021-6","article-title":"Clinical pharmacokinetics of new antiepileptic drugs.","volume":"67","author":"Walker","year":"1995","journal-title":"Pharmacol Ther"},{"key":"R62-2-20210129","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","article-title":"Clinical pharmacokinetics of levetiracetam.","volume":"43","author":"Patsalos","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R63-2-20210129","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1528-1167.2007.01090.x","article-title":"Pharmacokinetics of levetiracetam in infants and young children with epilepsy.","volume":"48","author":"Glauser","year":"2007","journal-title":"Epilepsia"},{"key":"R64-2-20210129","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1046\/j.1528-1157.2001.41300.x","article-title":"Pharmacokinetic study of levetiracetam in children.","volume":"42","author":"Pellock","year":"2001","journal-title":"Epilepsia"},{"key":"R65-2-20210129","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eplepsyres.2006.12.005","article-title":"Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate.","volume":"74","author":"Fountain","year":"2007","journal-title":"Epilepsy Res"},{"key":"R66-2-20210129","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics.","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacol Ther"},{"key":"R67-2-20210129","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0920-1211(93)90021-X","article-title":"Efficacy and safety of zonisamide: results of a multicenter study.","volume":"14","author":"Leppik","year":"1993","journal-title":"Epilepsy Res"},{"issue":"Suppl 1","key":"R68-2-20210129","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.seizure.2004.04.020","article-title":"Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies.","volume":"13","author":"Miura","year":"2004","journal-title":"Seizure"},{"key":"R69-2-20210129","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/cpt1979261114","article-title":"Plasma chlorpromazine concentrations in children with behavioral disorders and mental illness.","volume":"26","author":"Rivera-Calimlim","year":"1979","journal-title":"Clin Pharmacol Ther"},{"key":"R70-2-20210129","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00007691-198204000-00006","article-title":"Problems in therapeutic blood monitoring of chlorpromazine.","volume":"4","author":"Rivera-Calimlim","year":"1982","journal-title":"Ther Drug Monit"},{"key":"R71-2-20210129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00007691-197901000-00004","article-title":"Haloperidol plasma level monitoring in pediatric patients.","volume":"1","author":"Morselli","year":"1979","journal-title":"Ther Drug Monit"},{"key":"R72-2-20210129","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00004714-198810000-00009","article-title":"Pharmacokinetics of lithium carbonate in children.","volume":"8","author":"Vitiello","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"R73-2-20210129","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/0006-3223(95)00596-X","article-title":"Prolactin monitoring of haloperidol and pimozide treatment in children with Tourettes syndrome.","volume":"40","author":"Sallee","year":"1996","journal-title":"Biol Psychiatry"},{"key":"R74-2-20210129","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.","volume":"14","author":"Beasley","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"R75-2-20210129","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00004714-200004000-00015","article-title":"Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia.","volume":"20","author":"Grothe","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"R76-2-20210129","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4088\/JCP.v61n0403","article-title":"Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders.","volume":"61","author":"McConville","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R77-2-20210129","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/01.chi.0000219832.23849.31","article-title":"Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder.","volume":"45","author":"Findling","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R78-2-20210129","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004714-200302000-00012","article-title":"Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia.","volume":"23","author":"Frazier","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"R79-2-20210129","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","article-title":"Ziprasidone treatment of children and adolescents with Tourettes syndrome: a pilot study.","volume":"39","author":"Sallee","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R80-2-20210129","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/01.chi.0000215347.93902.3e","article-title":"Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents.","volume":"45","author":"Sallee","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R81-2-20210129","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.clinthera.2007.07.026","article-title":"Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders.","volume":"29","author":"Aman","year":"2007","journal-title":"Clin Ther"},{"key":"R82-2-20210129","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0140-6736(05)66915-2","article-title":"Attention-deficit hyperactivity disorder.","volume":"366","author":"Biederman","year":"2005","journal-title":"Lancet"},{"key":"R83-2-20210129","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-2125.1979.tb01046.x","article-title":"Pharmacokinetics of methylphenidate in hyperkinetic children.","volume":"8","author":"Hungund","year":"1979","journal-title":"Br J Clin Pharmacol"},{"key":"R84-2-20210129","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1542\/peds.69.6.688","article-title":"Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate.","volume":"69","author":"Shaywitz","year":"1982","journal-title":"Pediatrics"},{"key":"R85-2-20210129","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF00449120","article-title":"Metilphenidate oral dose plasma concentrations and behavioural response in children.","volume":"76","author":"Winsberg","year":"1982","journal-title":"Psychopharmacology"},{"key":"R86-2-20210129","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0022-3565(25)21542-7","article-title":"Pharmacokinetics of methylphenidate in man, rat and monkey.","volume":"226","author":"Wargin","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"R87-2-20210129","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1542\/peds.72.1.56","article-title":"Methylphenidate hydrochloride given with or before breakfast: II. Effects on plasma concentration of methylphenidate and ritalinic acid.","volume":"72","author":"Chan","year":"1983","journal-title":"Pediatrics"},{"key":"R88-2-20210129","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00007691-198412000-00001","article-title":"Clinical correlates of methylphenidate blood levels.","volume":"6","author":"Gualtieri","year":"1984","journal-title":"Ther Drug Monit"},{"key":"R89-2-20210129","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0022-5347(25)00353-2","article-title":"Stereoselective disposition of methylphenidate in children with attention-deficit disorder.","volume":"241","author":"Srinivas","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"R90-2-20210129","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/01.ftd.0000145514.18300.30","article-title":"Methylphenidate unintentional ingestion in preschool children.","volume":"27","author":"Bailey","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R91-2-20210129","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1089\/cap.2006.16.416","article-title":"Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens.","volume":"16","author":"Teicher","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R92-2-20210129","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/cap.2007.0043","article-title":"Pharmacokinetics of methylphenidate in preschoolers with attention-deficit\/hyperactivity disorder.","volume":"17","author":"Wigal","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R93-2-20210129","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1177\/0091270007299759","article-title":"Single-dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with attention-deficit\/hyperactivity disorder.","volume":"47","author":"Quinn","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"R94-2-20210129","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/104454603321666199","article-title":"Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder.","volume":"13","author":"Witcher","year":"2003","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R95-2-20210129","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/cap.2006.0044","article-title":"A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit\/hyperactivity disorder combined type.","volume":"17","author":"Findling","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R96-2-20210129","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1517\/14656566.7.5.545","article-title":"Pharmacological treatment options for panic disorder in children and adolescents.","volume":"7","author":"Masi","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"R97-2-20210129","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00007691-198010000-00002","article-title":"Preliminary observations of the significance of monitoring tricyclic antidepressant plasma levels in the pediatric patient.","volume":"2","author":"Dugas","year":"1980","journal-title":"Ther Drug Monit"},{"key":"R98-2-20210129","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00007691-198412000-00010","article-title":"Monitoring of serum levels of imipramine and desipramine and individualization of dose in enuretic children.","volume":"6","author":"De Gatta","year":"1984","journal-title":"Ther Drug Monit"},{"key":"R99-2-20210129","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00004714-198710000-00005","article-title":"Child and adolescent nortriptyline single dose pharmacokinetic parameters: final report.","volume":"7","author":"Geller","year":"1987","journal-title":"J Clin Psychopharmacol"},{"key":"R100-2-20210129","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00004714-198410000-00006","article-title":"Nortriptyline pharmacokinetic parameters in depressed children and adolescents: preliminary data.","volume":"4","author":"Geller","year":"1984","journal-title":"J Clin Psychopharmacol"},{"key":"R101-2-20210129","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1176\/ajp.143.10.1283","article-title":"Preliminary data on the relationship between nortriptyline plasma level and response in depressed children.","volume":"143","author":"Geller","year":"1986","journal-title":"Am J Psychiatry"},{"key":"R102-2-20210129","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3109\/03602538308991414","article-title":"Pharmacokinetics of intravenous morphine in balanced anesthesia: studies in children.","volume":"14","author":"Vandenberghe","year":"1983","journal-title":"Drug Metab Rev"},{"key":"R103-2-20210129","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/00000542-198612000-00005","article-title":"Epidural morphine in children: pharmacokinetics and CO2 sensitivity.","volume":"65","author":"Attia","year":"1986","journal-title":"Anesthesiology"},{"key":"R104-2-20210129","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00000542-198702000-00005","article-title":"Morphine pharmacokinetics in early infancy.","volume":"66","author":"Lynn","year":"1987","journal-title":"Anesthesiology"},{"key":"R105-2-20210129","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0304-3959(87)90022-4","article-title":"Cerebrospinal fluid and plasma pharmacokinetics of morphine infusions in pediatric cancer patients and rhesus monkeys.","volume":"30","author":"Greene","year":"1987","journal-title":"Pain"},{"key":"R106-2-20210129","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0022-3476(05)81102-3","article-title":"Pharmacokinetics of a single dose of morphine in preterm infants during the first week of life.","volume":"117","author":"Bhat","year":"1990","journal-title":"J Pediatr"},{"key":"R108-2-20210129","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/1053-0770(93)90158-H","article-title":"Morphine pharmacokinetics in children following cardiac surgery: effects of disease and inotropic support.","volume":"7","author":"Dagan","year":"1993","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R109-2-20210129","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1651-2227.1994.tb12976.x","article-title":"Morphine pharmacokinetics in premature and mature newborn infants.","volume":"83","author":"Mikkelsen","year":"1994","journal-title":"Acta Paediatr"},{"key":"R110-2-20210129","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1046\/j.1365-2125.1996.03539.x","article-title":"Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions.","volume":"41","author":"Barrett","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"R111-2-20210129","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/bja\/60.6.623","article-title":"Comparative plasma concentration profiles after i.v., i.m. and rectal administration of pethidine in children.","volume":"60","author":"Jacobsen","year":"1988","journal-title":"Br J Anaesth"},{"key":"R112-2-20210129","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/clpt.1992.153","article-title":"Pharmacokinetics and pharmacodynamics of intravenous meperidine in neonates and infants.","volume":"52","author":"Pokela","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"R113-2-20210129","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/bja\/71.6.823","article-title":"Pharmacokinetics of i.v. and rectal pethidine in children undergoing ophthalmic surgery.","volume":"71","author":"Hamunen","year":"1993","journal-title":"Br J Anaesth"},{"key":"R114-2-20210129","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2125.1989.tb05418.x","article-title":"Pharmacokinetics of intravenous buprenorphine in children.","volume":"28","author":"Olkkola","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"R115-2-20210129","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2125.1993.tb04220.x","article-title":"The pharmacokinetics and physiological effects of buprenorphine infusion in premature neonates.","volume":"36","author":"Barrett","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"R116-2-20210129","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0773.1993.tb01547.x","article-title":"Pharmacokinetics and pharmacodynamics of pentazocine in children.","volume":"73","author":"Hamunen","year":"1993","journal-title":"Pharmacol Toxicol"},{"key":"R117-2-20210129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2125.1994.tb04324.x","article-title":"Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children.","volume":"38","author":"Olkkola","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"R118-2-20210129","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2165\/00003088-200443090-00004","article-title":"Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children.","volume":"43","author":"Kokki","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R119-2-20210129","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1460-9592.2005.01571.x","article-title":"Marked variation in oxycodone pharmacokinetics in infants.","volume":"15","author":"Pokela","year":"2005","journal-title":"Paediatr Anaesth"},{"key":"R120-2-20210129","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2165\/00003088-200645070-00009","article-title":"Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children.","volume":"45","author":"Kokki","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R121-2-20210129","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0022-3565(25)39454-1","article-title":"Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol.","volume":"267","author":"Raffa","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"R122-2-20210129","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/oxfordjournals.bja.a013437","article-title":"Pharmacokinetics of tramadol in children after i.v. or caudal epidural administration.","volume":"84","author":"Murthy","year":"2000","journal-title":"Br J Anaesth"},{"key":"R123-2-20210129","first-page":"109","article-title":"Pharmacokinetics of oral tramadol drops for postoperative pain relief in children aged 4 to 7 years-a pilot study.","volume":"49","author":"Payne","year":"2002","journal-title":"Anesth Prog"},{"key":"R124-2-20210129","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/bja\/aeh178","article-title":"Pharmacokinetics of rectal tramadol in postoperative paediatric patients.","volume":"93","author":"Zwaveling","year":"2004","journal-title":"Br J Anaesth"},{"key":"R125-2-20210129","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0387-7604(86)80120-6","article-title":"Pharmacokinetics of rectal diazepam in the prevention of recurrent febrile convulsions.","volume":"8","author":"Minagawa","year":"1986","journal-title":"Brain Dev"},{"key":"R126-2-20210129","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.0306-5251.2001.01529.x","article-title":"Pharmacokinetics and anticonvulsant effects of diazepam in children with severe falciparum malaria and convulsions.","volume":"53","author":"Ogutu","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"R127-2-20210129","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/clpt.1987.91","article-title":"Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy.","volume":"41","author":"Relling","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"R128-2-20210129","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0022-3476(89)80713-9","article-title":"Lorazepam pharmacodynamics and pharmacokinetics in children.","volume":"114","author":"Relling","year":"1989","journal-title":"J Pediatr"},{"key":"R129-2-20210129","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/clpt.1991.117","article-title":"Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine.","volume":"50","author":"Crom","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"R130-2-20210129","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0022-3476(05)80925-4","article-title":"Pharmacokinetics of lorazepam in critically ill neonates with seizures.","volume":"120","author":"McDermott","year":"1992","journal-title":"J Pediatr"},{"key":"R131-2-20210129","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00003088-199835010-00003","article-title":"Clinical pharmacology of midazolam in infants and children.","volume":"35","author":"Blumer","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"R132-2-20210129","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/bja\/61.3.302","article-title":"A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery.","volume":"61","author":"Mathews","year":"1988","journal-title":"Br J Anaesth"},{"key":"R133-2-20210129","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0022-3476(05)82066-9","article-title":"Pharmacokinetic and pharmacodynamic study of midazolam in children during esophagogastroduodenoscopy.","volume":"119","author":"Tolia","year":"1991","journal-title":"J Pediatr"},{"key":"R134-2-20210129","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00679782","article-title":"The pharmacokinetics of midazolam in paediatric patients.","volume":"37","author":"Payne","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"key":"R135-2-20210129","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF00266357","article-title":"Pharmacokinetics of midazolam during continuous infusion in critically ill neonates.","volume":"42","author":"Jacqz-Aigrain","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"R136-2-20210129","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/bja\/70.3.286","article-title":"Pharmacokinetics of flumazenil and midazolam.","volume":"70","author":"Jones","year":"1993","journal-title":"Br J Anaesth"},{"key":"R137-2-20210129","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1177\/00912700122012832","article-title":"The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration.","volume":"41","author":"Reed","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"R138-2-20210129","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1067\/mcp.2001.120683","article-title":"Pharmacokinetics and metabolism of intravenous midazolam in preterm infants.","volume":"70","author":"de Wildt","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"R139-2-20210129","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1046\/j.1365-2125.2002.01223.x","article-title":"Pharmacokinetics and metabolism of oral midazolam in preterm infants.","volume":"53","author":"de Wildt","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"R140-2-20210129","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/cp.1999.v66.100596001","article-title":"Pharmacokinetics and tolerance of flunitrazepam in neonates and in infants.","volume":"66","author":"Pariente-Khayat","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"R141-2-20210129","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00004583-199804000-00016","article-title":"Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy.","volume":"37","author":"Alderman","year":"1998","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R142-2-20210129","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/00004583-200209000-00003","article-title":"Sertraline pharmacokinetics and dynamics in adolescents.","volume":"41","author":"Axelson","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R143-2-20210129","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/cap.2006.16.117","article-title":"Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents.","volume":"16","author":"Alderman","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R144-2-20210129","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/sj.npp.1300960","article-title":"Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder.","volume":"31","author":"Findling","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"R145-2-20210129","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/00128072-199901030-00002","article-title":"Pharmacological treatment of depression in children and adolescents.","volume":"1","author":"Findling","year":"1999","journal-title":"Paediatr Drugs"},{"key":"R146-2-20210129","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archpsyc.1997.01830230069010","article-title":"A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression.","volume":"54","author":"Emslie","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"R147-2-20210129","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/00004714-200212000-00006","article-title":"Fluoxetine pharmacokinetics in pediatric patients.","volume":"22","author":"Wilens","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"R148-2-20210129","first-page":"1361","article-title":"Single-dose pharmacokinetic study of escitalopram in adolescents and adults [abstract].","volume":"23","author":"Periclou","year":"2003","journal-title":"Pharmacotherapy"},{"key":"R149-2-20210129","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1097\/01.chi.0000143546.28821.11","article-title":"Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents.","volume":"43","author":"Labellarte","year":"2004","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R150-2-20210129","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/0091270003254638","article-title":"Pharmacokinetics of sumatriptan nasal spray in adolescents.","volume":"43","author":"Christensen","year":"2003","journal-title":"J Clin Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e31819f3328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T16:44:21Z","timestamp":1739119461000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-200906000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":147,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31819f3328","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}